

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bósze**
Montréal (Canada) *Budapest (Hungary)*

Associate Editor

M. Marchetti
Montréal (Canada)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

H.H. Allen, <i>London, Ontario (Canada)</i>	M. Friedrich, <i>Luebeck (Germany)</i>	C. Marth, <i>Innsbruck (Austria)</i>
S.O. Anteby, <i>Jerusalem (Israel)</i>	A.F. Fuller Jr., <i>Boston, MA (USA)</i>	Leon F. A. G. Massuger, <i>Nijmegen (The Netherlands)</i>
P. Audet-Lapointe, <i>Montreal (Canada)</i>	H.E. Geisler, <i>Indianapolis, IN (USA)</i>	J. Menczer, <i>Savyon (Israel)</i>
A. Ayhan, <i>Ankara (Turkey)</i>	A. Gerbault, <i>Villejuif (France)</i>	J. Monsonego, <i>Paris (France)</i>
O. Balat, <i>Graziantep (Turkey)</i>	A. Gorins, <i>Paris (France)</i>	A. Pinotti, <i>São Paulo (Brazil)</i>
H.K. Barber, <i>New York, NY (USA)</i>	A.P.M. Heintz, <i>Utrecht (The Netherlands)</i>	S.M. Piver, <i>Buffalo, NY (USA)</i>
A. Basta, <i>Krakow (Poland)</i>	L. Ioannidou-Mouzaka, <i>Athens (Greece)</i>	S. Rakar, <i>Ljubljana (Slovenia)</i>
H.C. Bender, <i>Dusseldorf (Germany)</i>	J.A. Jordan, <i>Birmingham, England (UK)</i>	K.S. Raju, <i>London, England (UK)</i>
P.L. Benedetti Panici, <i>Rome (Italy)</i>	A.I. Karseladze, <i>Moscow (Russia)</i>	J.H. Shepherd, <i>London, England (UK)</i>
T. Charkviani, <i>Tbilisi (Georgia)</i>	J. Klastersky, <i>Bruxelles (Belgium)</i>	J. Stelmachów, <i>Warsaw (Poland)</i>
D. Dargent, <i>Lyon (France)</i>	E. Kubista, <i>Vienna (Austria)</i>	L. Ungár, <i>Budapest (Hungary)</i>
C.F. De Oliveira, <i>Coimbra (Portugal)</i>	A.P. Kudelka, <i>Houston, TX (USA)</i>	J.B. Vermorken, <i>Edegem (Belgium)</i>
S. Dexeus Jr., <i>Barcelona (Spain)</i>	T. Maggino, <i>Padua (Italy)</i>	P. Vírtej, <i>Bucharest (Romania)</i>
G. De Palo, <i>Milan (Italy)</i>	J. Markowska, <i>Poznan (Poland)</i>	P.-H. Wang, <i>Taipei (Taiwan)</i>
G.R. Di Paola, <i>Buenos Aires (Argentina)</i>		R. Winter, <i>Graz (Austria)</i>
F. Di Re, <i>Milan (Italy)</i>		Y. Yokoyama, <i>Hirosaki (Japan)</i>
P. Di Saia, <i>Orange, CA (USA)</i>		

Publisher Organization:

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc
Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242-4893640 - Fax +514-4854513 - E-mail: canlux@qc.aira.com
www.irog.net

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

www.irog.net

General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@qc.aira.com - www.irog.net.

RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

European Journal of Gynaecological Oncology

www.irog.net

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, PO Box 46, 1031 Budapest, Hungary, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@mail.matav.hu.

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. **Manuscripts submitted for publication cannot be returned.**

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts*, typed and double spaced should be submitted **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: *Summary* (*purpose of investigation, methods, results, conclusion - about 150 words*), *Key words*, *Content* (a 20-word summary), *Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement* (if any), *References, Tables, Legends*.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

DISTINGUISHED EXPERT SERIES

Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis 5

K.J. Syrjänen - *Rome, ITALY*

This review describes the potentially useful strategies of how immunohistochemistry (IHC) can be used to assess the molecular pathogenesis of cervical cancer based on the author's own experience in a number of prospective cohort studies over the past 25 years.

EDITORIAL ARTICLE

Possibilities and limitation of endoscopic procedures in oncological gynaecology 21

J. Stelmachów, B. Śpiewankiewicz - *Warsaw, POLAND*

Laparoscopy and hysteroscopy are commonly used in gynaecological practice. In cases of gynaecological cancer the use of endoscopic techniques, despite becoming more frequent, causes many controversies.

REVIEW ARTICLE

Restaging in gynaecological cancers 25

A. Ayhan, H. Celik, F. Coskun, C. Baykal, M.C. Salman, G. Aksan - *Ankara, TURKEY*

A review of the literature about the value of restaging in gynaecological cancers is presented.

ORIGINAL ARTICLES

Intratumoral oxygenation of invasive squamous cell carcinoma of the vulva is not correlated with regional lymph node metastasis 31

J.E. Stone, R. Parker, C.B. Gilks, E.J. Stanbridge, S.Y. Liao, C. Aquino-Parsons - *Vancouver, BC (USA)*

Various methods of measuring tumour oxygenation of invasive squamous cell carcinoma of the vulva do not appear to predict nodal metastasis.

Primary lymphoma of the cervix uteri: a diagnostic challenge. Report of two cases and review of the literature 36

N. Van Renterghem, P. De Paepe, R. Van den Broecke, C. Bourgain, R. Serreyn - *Brussels, BELGIUM*

Primary non-Hodgkin's lymphoma of the cervix and vagina is uncommon. The diagnosis can be difficult and often immunohistochemical analysis and molecular techniques are required to confirm it.

Human papillomavirus infection in relation to mild dyskaryosis in conventional cervical cytology 39

E. Vrtačnik Bokal, S. Rakar, A. Možina, M. Poljak - *Ljubljana, SLOVENIA*

HPV testing should be considered as a complementary method to cytology in patients with mild dyskaryosis.

Evaluation of soluble tumour necrosis factor alpha receptors p55 and p75 in ovarian cancer patients 43

T. Opala, P. Rzymiski, M. Wilczak, J. Woźniak - *Poznan, POLAND*

Serum TNF alpha receptors p55 and p75 in malignant ovarian tumours were evaluated. Their concentrations were elevated in malignancy but only p55 correlated with the morphologic ultrasound score and CA-125. Neither receptor was any better in detecting power than CA-125.

Epidemiological aspects of ovarian malignancies in North Sardinia in the period 1992-2001 47

A. Cossu, M. Budroni, G. Capobianco, D. Pirino, G. Palmieri, S. Dessole, F. Tanda, R. Cesaraccio, P.L. Cherchi - *Sassari, ITALY*

The incidence of malignant ovarian tumors in the province of Sassari in the period 1992-2001 is reported.

An ultrasonographic morphological index for prediction of ovarian tumor malignancy 51

D. Szperek, R. Moszynski, W. Ziętkowiak, M. Spaczynski, S. Sajdak - *Poznan, POLAND*

The ultrasonographic morphological Poznan index was created to improve the probability of proper decision making in patients with ovarian tumors.

Endometrial cancer in polyps: A clinical study of 27 cases 55

C. Martín-Ondarza, A. Gil-Moreno, L. Torres-Cuesta, Á. García, F. Eyzaguirre, B. Díaz-Feijoo, J. Xercavins - *Barcelona, SPAIN*

Endometrial cancer in polyps has an excellent prognosis, therefore, postmenopausal women with sonographic findings of polyps should undergo hysteroscopy and biopsy to exclude neoplastic changes.

Risk factors and prognostic factors in patients with double primary cancer: Epithelial ovarian cancer and breast cancer	59
M. Cvelbar, M. Uršič-Vrscaj, S. Rakar - <i>Ljubljana, SLOVENIA</i>	
A study on risk factors and prognostic factors in patients with double primary cancer of the breast and ovary in light of possible BRCA1/2 mutations is presented.	
The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma	64
M.A. Osmanağaoğlu, S. Kadioğlu, S. Osmanağaoğlu, H. Bozkaya, A. Reis, Y. Tekelioğlu - <i>Trabzon, TURKEY</i>	
To determine whether p53 expression and DNA ploidy are related to the traditional prognostic indicators in patients with endometrial cancer.	
Ovarian cystic teratoma with primary epithelial cell melanoma	71
R. Zarbo, G. Scibilia, G. Conoscenti, P. Scollo - <i>Catania, ITALY</i>	
Primary malignant melanoma arising in an ovarian cystic teratoma is a rare disease. Prognosis is generally poor despite surgery and chemotherapy.	
Diagnostic value of the PDD method in evaluation of vulvar lesions	75
Z. Nowakowski, J. Stelmachów, B. Śpiewankiewicz, G. Gerulewicz - <i>Warsaw, POLAND</i>	
The projected purpose of the study in cases of vulvar lesions was realised by performing a detailed comparative analysis of the sensitivity, specificity and diagnostic efficacy of PDD and vulvoscopy, as compared with the histological evaluation of the excised lesions.	
Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma	79
I. Dunder, B. Berker, C. Atabekoglu, T. Bilgin - <i>Bursa, TURKEY</i>	
A weekly paclitaxel regimen has encouraging antitumor activity in recurrent ovarian cancer with acceptable toxicity.	
Quantitative telomerase activity in malignant, benign and normal gynecological tissues	83
B. Saygan-Karamürsel, G. Dikmen, P. Dogan, T. Aksu, S. Guven, A. Ayhan - <i>Ankara, TURKEY</i>	
The telomerase-PCR ELISA method can be used to differentiate malignant gynecological tissues with a high sensitivity and specificity.	
Granzyme B as a prognostic marker of cervical intraepithelial neoplasia	87
M.C. Kondo, J.C.L. Ribalta, I.D.G. da Silva, M.T.S. Alves, G.R. de Azevedo Focchi, N.V. Martins, J. Focchi - <i>São Paulo, BRAZIL</i>	
Granzyme B (GrB) expression in 12 cervical carcinomas, 33 intraepithelial neoplasias and normal cervixes were quantified. GrB is suggested as a prognostic marker.	
Value of glutathion-S transferase pi as a prognostic factor in epithelial ovarian carcinoma	90
P. Saip, S. Tuzlali, K. Demir, B. Sakar, E. Yavuz, S. Berkman, E. Bengisu, E. Topuz - <i>Istanbul, TURKEY</i>	
The association between glutathion-S transferase pi (GSTn) and clinicopathological parameters, chemotherapy response and survival were investigated in epithelial ovarian cancer patients.	
Expression of E-cadherin in squamous cell carcinomas of the cervix with correlations to clinicopathological features	95
M. Yaldiz, A.U. Hakverdi, G. Bayhan, Z. Akkuş - <i>Diyarbakir, TURKEY</i>	
The aim of this study was to evaluate expression of E-cadherin in cervical carcinoma. Reduced E-cadherin expression may be an important factor during the process of metastasis.	
Antiestrogenic therapy in breast cancer and endometrial modifications	99
B. Mossa, R. Marziani, K. Hannuna, T. Iuele, J. Melluso, C. Napolitano - <i>Rome, ITALY</i>	
A higher incidence of endometrial pathology was found in symptomatic postmenopausal tamoxifen treated patients (27.2% vs 19.5%) between the third and fifth year of treatment.	
CASE REPORTS	
Vulvar invasive squamous cell carcinoma occurring in a young woman with systemic lupus erythematosus	103
B. Piura, A. Rabinovich, R. Shaco-Levy, S. Sukenik - <i>Beer-Sheva, ISRAEL</i>	
A rare case of vulvar carcinoma in a young SLE patient is presented and the association between SLE and malignancy is discussed.	
Primary squamous cell carcinoma of endometrium: A case report	106
Ž. Duić, V. Kukura, G. Zovko, S. Ciglar, M. Podobnik, I. Krivak Bolanča, S. Gašparov - <i>Zagreb, CROATIA</i>	
Treatment and follow-up of primary squamous cell carcinoma of the endometrium in a virgin postmenopausal woman is presented.	

Coexistence of Brenner tumor and struma ovarii: case report	109
K. Takeuchi, C. Ohbayashi, S. Kitazawa, N. Ohara, T. Maruo - <i>Kobe, JAPAN</i>	
We describe a case of coexisting Brenner tumor and struma ovarii, which supports the germ cell theory of Brenner tumor.	
Laparoscopic uterine artery dissection in an undiagnosed endometrial stromal sarcoma. Case report	111
Z. Holub, Z. Rokyta, L. Kliment - <i>Kladno, CZECH REPUBLIC</i>	
A case of endometrial stromal sarcoma discovered after dissection of the uterine vessels for a symptomatic fibroid in a 24-year-old woman is presented.	
Endometrial stromal sarcoma arising in extrauterine endometriosis: A case report	113
D. Kovač, I. Gašparović, M. Jašić, D. Fučkar, R. Dobi-Babić, H. Haller - <i>Rijeka, CROATIA</i>	
Endometrial stromal sarcoma occurred in extrauterine endometriosis in a 46-year-old woman with a gynecological history.	
Pelvic retroperitoneal schwannoma presenting as a gynecologic mass: Case report	117
I. Korkontzelos, E. Tsimoyiannis, A. Zagaliki, A. Demou, E. Karabina, N. Antoniou - <i>Ioannina, GREECE</i>	
Retroperitoneal schwannomas with intrapelvic extension comprise rare tumors difficult to diagnose that present infrequently as gynecologic masses.	
Primary ovarian leiomyosarcoma: A case report	120
E. Kuscu, S. Erkanli, A. Haberal, T. Ergin, H. Ozdemir, B. Demirhan - <i>Ankara, TURKEY</i>	
An unusual case of primary ovarian leiomyosarcoma that was diagnosed in the setting of a slightly enlarged irregular post-menopausal ovary is presented.	
Laparoscopic evaluation of metastatic ovarian cancer: A case report	123
A.C. Iyibozkurt, S.E. Akhan, S. Topuz, I. Citil, S. Berkman - <i>Istanbul, TURKEY</i>	
Presentation of a patient with gastric tumor with ovarian metastasis diagnosed by laparoscopy: a safe and an effective diagnostic option.	

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

Vol. XXVI, Number 1, 2005

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Publisher office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@qc.aira.com - www.irog.net

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy